Vigil Platform
Other Solid Tumors
Research/Pre-clinicalActive
Key Facts
About Gradalis
Gradalis is a private, late-stage biotech advancing Vigil, a personalized cancer immunotherapy platform. Its lead program has demonstrated a significant survival benefit in a subset of ovarian cancer patients in a Phase 2b trial, with data published in a peer-reviewed journal. The company is positioning Vigil as a potential treatment for various solid tumors, either as a monotherapy or in combination with other regimens, representing a targeted approach in the immuno-oncology space.
View full company profileTherapeutic Areas
Other Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SBP-101 (Ivospemin) | Panbela Therapeutics | Research |
| Ivonescimab (AK112) | Akeso | Phase III |
| VDC Platform | Aura Biosciences | Discovery |
| Mitazalimab | Alligator Bioscience AB | Phase 1/2 |